Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE vs SBRT for Residual or Recurrent HCC
NCT02762266Phase 3Terminated
- Sponsor
- Stanford University
- Start
- Feb 2016
- Primary completion
- Dec 2022
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Stanford University. Primary endpoint: Freedom From Local Progression at 12 months. Started Feb 2016; status: terminated.
Beyond the preview
Go deeper on NCT02762266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762266.